The international surgical journal with global reach

Five-year analysis of adjuvant dabrafenib plus trametinib in Stage III Melanoma. N Engl J Med 2020; 383: 1139-1148.

Published: 17th November 2020

Authors: Dummer R, Hauschild A, Santinami M, Atkinson V, Mandala M, Kirkwood JM et al.

Conclusion

A total of 870 patients were included originally. Adjuvant treatment was given for one year. At median follow-up of 60 months, more patients were alive without distant metastases in the active treatment group: 65 versus 54 per cent, hazard rate ratio for relapse or death 0.55, 95% confidence interval 0.42 to 0.61.

Pubmed Link